Evidence map›Paper›PMID 41009641›Full record

ArticleInternational journal of molecular sciences2025

Proteomic Analysis Uncovers Enhanced Inflammatory Phenotype and Distinct Metabolic Changes in IDH1 Mutant Glioma Cells.

Sigrid Ravn Berg, Alessandro Brambilla, Lars Hagen, Animesh Sharma, Cathrine Broberg Vågbø, Nina Beate Liabakk, Miroslava Kissova, Miquel Arano Barenys, Magnar Bjørås, Sverre Helge Torp and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal of molecular sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Sigrid Ravn BergDepartment of Clinical and Molecular Medicine, Norwegian University of Science and Technology, 7491 Trondheim, Norway.
Alessandro BrambillaDepartment of Clinical and Molecular Medicine, Norwegian University of Science and Technology, 7491 Trondheim, Norway.ORCID 0009-0003-7990-0190
Lars HagenDepartment of Clinical and Molecular Medicine, Norwegian University of Science and Technology, 7491 Trondheim, Norway.
Animesh SharmaDepartment of Clinical and Molecular Medicine, Norwegian University of Science and Technology, 7491 Trondheim, Norway.ORCID 0000-0002-8791-4635
Cathrine Broberg VågbøDepartment of Clinical and Molecular Medicine, Norwegian University of Science and Technology, 7491 Trondheim, Norway.
Nina Beate LiabakkDepartment of Clinical and Molecular Medicine, Norwegian University of Science and Technology, 7491 Trondheim, Norway.ORCID 0000-0001-9537-2584
Miroslava KissovaDepartment of Clinical and Molecular Medicine, Norwegian University of Science and Technology, 7491 Trondheim, Norway.ORCID 0000-0001-9798-9131
Miquel Arano BarenysDepartment of Clinical and Molecular Medicine, Norwegian University of Science and Technology, 7491 Trondheim, Norway.ORCID 0009-0005-1954-3296
Magnar BjøråsDepartment of Clinical and Molecular Medicine, Norwegian University of Science and Technology, 7491 Trondheim, Norway.ORCID 0000-0001-8759-1170
Sverre Helge TorpDepartment of Clinical and Molecular Medicine, Norwegian University of Science and Technology, 7491 Trondheim, Norway.ORCID 0000-0001-8345-6852
Geir SlupphaugDepartment of Clinical and Molecular Medicine, Norwegian University of Science and Technology, 7491 Trondheim, Norway.ORCID 0000-0002-7498-3500

Funding

The Liaison Committee between the Central Norway regional Health Authority and Norwegian University of Science and Technology 3253-02-04-22
6 · The paper itself

Abstract

Isocitrate dehydrogenase 1 (IDH1) mutations are key drivers of glioma biology, influencing tumor aggressiveness and treatment response. To elucidate their molecular impact, we performed proteome analysis on patient-derived (PD) and U87MG glioma cell models with either mutant or wild-type IDH1. We quantified over 6000 protein groups per model, identifying 1594 differentially expressed proteins in PD-AS (IDH1

Indexed as

Brain NeoplasmsGliomaInflammationIsocitrate DehydrogenaseMutationProteomicsCell Line, TumorGene Expression Regulation, NeoplasticHumansPhenotypeProteomeIDH1 protein, humanIsocitrate DehydrogenaseProteomeantigen presentationDNA and histone demethylasesDNA repairglioma biomarkersinterferon signalingisocitrate dehydrogenase mutationsproteomicsRNA

Identifiers

PMID41009641
PMCPMC12470816

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.